Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | CCND1 | P24385 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605568 | 0.85 | KMT2A (0.56) | KMT2APOLBRECQLHSD17B10L3MBTL1 | |
| SCHEMBL12605547 | 0.80 | GRIN2B (0.57) | KMT2APOLBKDM4ELMNAALDH1A1 | |
| SCHEMBL16897887 | 0.79 | KMT2A (0.52) | KMT2AL3MBTL1KDM4ECXCR3LMNA | |
| SCHEMBL16897912 | 0.78 | ALDH1A1 (0.47) | KMT2ATSHRDRD2DRD4DRD3 | |
| SCHEMBL30063707 | 0.73 | CDK4 (0.76) | KMT2ATSHRHSD17B10LMNACDK4 | |
| SCHEMBL734246 | 0.73 | CDK4 (0.76) | KMT2ATSHRHSD17B10LMNACDK4 | |
| SCHEMBL16117855 | 0.72 | KRAS (0.46) | KMT2AKDM4ECXCR3 | |
| SCHEMBL31672359 | 0.72 | KRAS (0.46) | KMT2AKDM4ECXCR3 | |
| SCHEMBL3990420 | 0.72 | LMNA (0.61) | KMT2ATSHRDRD2DRD4DRD3 | |
| SCHEMBL27518021 | 0.71 | CDK4 (0.73) | KMT2ATSHRHSD17B10LMNACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-10087151-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3091984-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885TSHR 2505/4885DRD2 2346/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | KMT2A 2162/4885TSHR 3319/4885DRD2 2516/4885 |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885TSHR 2505/4885DRD2 2346/4885 |
| US-10087151-B2 | Substituted benzoxazine and related compounds | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885TSHR 2505/4885DRD2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.